Literature DB >> 12843079

Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.

Viktoria Nurpeisov1, Selwyn J Hurwitz, Prem L Sharma.   

Abstract

The fluorescent dye-labeled dideoxynucleotide automated DNA sequencing system has been routinely used for monitoring the development of resistance mutations in human immunodeficiency virus type 1 reverse transcriptase (RT) and protease genes during therapy. This system has provided information regarding the presence of mixtures of nucleotides in the clinical samples but has not previously been validated for the quantitative determination between peak heights and relative DNA concentration. We evaluated this system by using various ratios of wild-type and mutated DNA fragments and by performing sequencing reactions at actual melting temperatures of specific primers. Several different ratios of purified DNA fragments containing mixtures of L74/V74 and M184/V184 were sequenced, and peak heights were measured. Regression analysis between ratios of peak heights and DNA concentration demonstrated a statistically significant linear correlation, suggesting that the quantification of two different species of DNA in a mixture could be achieved with the fluorescent dye-labeled dideoxynucleotide system. These strategies have broader implications for the quantification of replication fitness of viruses, particularly those containing RT mutations at codons 74 and 184.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843079      PMCID: PMC165373          DOI: 10.1128/JCM.41.7.3306-3311.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  HIV-1 drug resistance: can we overcome?

Authors:  Bluma G Brenner; Dan Turner; Mark A Wainberg
Journal:  Expert Opin Biol Ther       Date:  2002-10       Impact factor: 4.388

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness.

Authors:  Lucia Ometto; Davide De Forni; Fiorulla Patiri; Virginie Trouplin; Fabrizio Mammano; Vania Giacomet; Carlo Giaquinto; Daniel Douek; Richard Koup; Anita De Rossi
Journal:  AIDS       Date:  2002-04-12       Impact factor: 4.177

5.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors:  B A Larder; G Darby; D D Richman
Journal:  Science       Date:  1989-03-31       Impact factor: 47.728

6.  Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.

Authors:  Emanuele Nicastri; Loredana Sarmati; Gabriella d'Ettorre; Lucia Palmisano; Saverio G Parisi; Ilaria Uccella; Alessia Rianda; Ercole Concia; Vincenzo Vullo; Stefano Vella; Massimo Andreoni
Journal:  J Med Virol       Date:  2003-01       Impact factor: 2.327

7.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

8.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

9.  The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response.

Authors:  V Miller; T Stark; A E Loeliger; J M A Lange
Journal:  HIV Med       Date:  2002-04       Impact factor: 3.180

10.  Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Authors:  T Imamichi; S C Berg; H Imamichi; J C Lopez; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

View more
  13 in total

1.  AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

Authors:  Yue-Ying Wang; Guang-Biao Zhou; Tong Yin; Bing Chen; Jing-Yi Shi; Wen-Xue Liang; Xiao-Long Jin; Jian-Hua You; Guang Yang; Zhi-Xiang Shen; Jue Chen; Shu-Min Xiong; Guo-Qiang Chen; Feng Xu; Yi-Wei Liu; Zhu Chen; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-13       Impact factor: 11.205

2.  In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants.

Authors:  Xiaodong Zhao; Enmei Liu; Fu-Ping Chen; Wayne M Sullender
Journal:  J Virol       Date:  2006-09-27       Impact factor: 5.103

3.  Site-directed RNA editing by adenosine deaminase acting on RNA for correction of the genetic code in gene therapy.

Authors:  Md T A Azad; S Bhakta; T Tsukahara
Journal:  Gene Ther       Date:  2017-12-07       Impact factor: 5.250

4.  A strategy for developing a hammerhead ribozyme for selective RNA cleavage depending on substitutional RNA editing.

Authors:  Masatora Fukuda; Kei Kurihara; Yasuyoshi Tanaka; Masanobu Deshimaru
Journal:  RNA       Date:  2012-07-13       Impact factor: 4.942

5.  Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V.

Authors:  Prem L Sharma; James H Nettles; Anya Feldman; Kimberly Rapp; Raymond F Schinazi
Journal:  Antiviral Res       Date:  2009-06-23       Impact factor: 5.970

6.  A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.

Authors:  Himabindu Chunduri; David Rimland; Viktoria Nurpeisov; Clyde S Crumpacker; Prem L Sharma
Journal:  Virol J       Date:  2011-01-21       Impact factor: 4.099

7.  Predicting sites of ADAR editing in double-stranded RNA.

Authors:  Julie M Eggington; Tom Greene; Brenda L Bass
Journal:  Nat Commun       Date:  2011       Impact factor: 14.919

8.  Improved design of hammerhead ribozyme for selective digestion of target RNA through recognition of site-specific adenosine-to-inosine RNA editing.

Authors:  Masatora Fukuda; Kei Kurihara; Shota Yamaguchi; Yui Oyama; Masanobu Deshimaru
Journal:  RNA       Date:  2014-01-21       Impact factor: 4.942

9.  Profiling the DNA-binding specificities of engineered Cys2His2 zinc finger domains using a rapid cell-based method.

Authors:  Xiangdong Meng; Stacey Thibodeau-Beganny; Tao Jiang; J Keith Joung; Scot A Wolfe
Journal:  Nucleic Acids Res       Date:  2007-05-30       Impact factor: 16.971

10.  In vitro Fab display: a cell-free system for IgG discovery.

Authors:  Ryan L Stafford; Marissa L Matsumoto; Gang Yin; Qi Cai; Juan Jose Fung; Heather Stephenson; Avinash Gill; Monica You; Shwu-Hwa Lin; Willie D Wang; Mary Rose Masikat; Xiaofan Li; Kalyani Penta; Alex R Steiner; Ramesh Baliga; Christopher J Murray; Christopher D Thanos; Trevor J Hallam; Aaron K Sato
Journal:  Protein Eng Des Sel       Date:  2014-02-28       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.